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Approximately 15% of human prion disease is associated with autosomal-dominant pathogenic
mutations in the prion protein (PrP) gene. Previous attempts to model these diseases in mice have
expressed human PrP mutations in murine PrP, but this may have different structural
consequences. Here, we describe transgenic mice expressing human PrP with P102L or E200K
mutations and methionine (M) at the polymorphic residue 129. Although no spontaneous disease
developed in aged animals, these mice were readily susceptible to prion infection from patients
with the homotypic pathogenic mutation. However, while variant Creutzfeldt–Jakob disease (CJD)
prions transmitted infection efficiently to both lines of mice, markedly different susceptibilities to
classical (sporadic and iatrogenic) CJD prions were observed. Prions from E200K and classical
CJD M129 homozygous patients, transmitted disease with equivalent efficiencies and short
incubation periods in human PrP 200K, 129M transgenic mice. However, mismatch at residue
129 between inoculum and host dramatically increased the incubation period. In human PrP
102L, 129M transgenic mice, short disease incubation periods were only observed with
transmissions of prions from P102L patients, whereas classical CJD prions showed prolonged
and variable incubation periods irrespective of the codon 129 genotype. Analysis of disease-
related PrP (PrP
Sc) showed marked alteration in the PrP
Sc glycoform ratio propagated after
transmission of classical CJD prions, consistent with the PrP point mutations directly influencing
PrP
Sc assembly. These data indicate that P102L or E200K mutations of human PrP have differing
effects on prion propagation that depend upon prion strain type and can be significantly
influenced by mismatch at the polymorphic residue 129.
INTRODUCTION
Inherited prion diseases (IPDs) are fatal neurodegenerative
disorders caused by autosomal-dominant mutations in the
human PrP gene (PRNP), and constitute about 15% of all
human prion disease (Collinge, 2001, 2005; Kovacs et al.,
2002; Wadsworth et al., 2003; Mead, 2006). Over 30
mutations have been identified, but the precise biochemical
mechanisms that lead to disease remain unknown.
According to the ‘protein-only’ hypothesis (Griffith, 1967),
an abnormal isoform of host-encoded cellular prion
protein (PrP
C) is the principal, and possibly the sole,
constituent of the transmissible agent or prion (Prusiner,
1982; Collinge & Clarke, 2007). This hypothesis proposes
that the central pathogenic process is the conversion of
PrP
C to a disease-related isoform, PrP
Sc, through a
conformational change occurring either spontaneously or
during interaction with exogenous PrP
Sc. PrP
Sc consists of
aggregated misfolded PrP and distinct prion strains are
thought to be composed of different polymeric forms of
PrP (for recent review see Collinge & Clarke, 2007).
Importantly, IPDs may also be experimentally transmiss-
ible and it is thought that pathogenic mutations in PRNP
predispose mutant PrP
C to convert spontaneously to a
pathogenic isoform (Collinge & Palmer, 1992; Collinge,
2005; Collinge & Clarke, 2007). While patients with IPD
have traditionally been classified by the clinicopathological
syndromes of Gerstmann–Stra ¨ussler–Scheinker disease
(GSS), Creutzfeldt–Jakob disease (CJD) or fatal familial
insomnia (FFI), the advent of molecular genetic diagnosis
led to the recognition of considerable phenotypic hetero-
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(Collinge et al., 1989, 1990, 1992; Mallucci et al., 1999;
Kovacs et al., 2002; Wadsworth et al., 2006) and
subclassification of IPD by pathogenic mutation was
proposed (Collinge et al., 1992; Collinge & Prusiner, 1992).
The mutation at codon 200 of PRNP, which results in a
glutamic acid substitution by lysine (E200K) in PrP, is one
of the most prevalent, being responsible for the high
incidence of CJD amongst Libyan Jews and in areas of
Slovakia and Chile, and is recognized in many other
countries (Goldfarb et al., 1990, 1991; Hsiao et al., 1991;
Brown et al., 1992; Collinge et al., 1993; Kovacs et al.,
2002). Families with the E200K mutation demonstrate
varied clinical symptoms including uncommon features
such as fatal insomnia, pruritus and demyelinating
peripheral neuropathy or protracted dementia without
other distinguishing characteristics (Chapman et al., 1993).
Indeed, this form of IPD can present clinically and
pathologically like classic sporadic CJD (Chapman et al.,
1993), and although PRNP E200K homozygotes do not
seem to differ in clinical features from heterozygotes, a
statistically significant younger age at disease onset was
found for homozygotes (Simon et al., 2000). Penetrance for
the E200K mutation is age dependent and approaches
100% by 85 years of age (Chapman et al., 1993).
A proline to leucine substitution at codon 102 (P102L) of
human PrP is the most common mutation associated with
the GSS phenotype and was first reported in 1989 (Hsiao et
al., 1989). Many other families have now been documented
worldwide (Kovacs et al., 2002), including the original
Austrian family reported by Gerstmann, Stra ¨ussler and
Scheinker in 1936 (Kretzschmar et al., 1991; Hainfellner et
al., 1995). Progressive ataxia is the dominant clinical
feature, with dementia and pyramidal features occurring
later in a disease course typically much longer than that of
classical CJD. However, marked variability at both the
clinical and neuropathological levels is apparent, with some
patients developing a classical CJD-like phenotype with
early and rapidly progressive dementia (Hainfellner et al.,
1995; Barbanti et al., 1996; Majtenyi et al., 2000;
Wadsworth et al., 2006; Kretzschmar et al., 1992; Webb
et al., 2008). A recent study indicates that differential
recruitment of wild-type PrP into PrP
Sc may contribute to
phenotypic variability in atypical cases (Wadsworth et al.,
2006).
Polymorphism at residue 129 of human PrP [where either
methionine (M) or valine (V) can be encoded] not only
affects susceptibility to sporadic and acquired human prion
diseases (Palmer et al., 1991; Collinge et al., 1991; Lee et al.,
2001; Mead et al., 2003), but can affect the age of onset and
also modify the phenotypes of IPDs (Baker et al., 1991;
Poulter et al., 1992; Goldfarb et al., 1992; Mead et al.,
2006).
Early attempts to transmit IPDs in non-human primates
(Brown et al., 1994) and wild-type mice (Tateishi et al.,
1996) resulted in poor transmission rates, resulting in the
important issue of whether or not all IPDs are experi-
mentally transmissible being unresolved (Collinge, 1997).
Transgenic mice expressing high levels of mouse PrP 101L
(equivalent to 102L in human PrP) spontaneously
developed neurological dysfunction at 166 days of age
(Hsiao et al., 1990). PrP
Sc levels were low or undetectable,
and brain extracts from affected mice did not transmit
CNS degeneration to wild-type mice, but transmission to
hamsters and Tg(GSSPrP)196 mice, expressing lower levels
of the same mutant transgene product, was reported
(Hsiao et al., 1994; Telling et al., 1996a). These
Tg(GSSPrP)196 mice have subsequently been reported to
develop spontaneous disease at advanced age (Tremblay et
al., 2004; Nazor et al., 2005). It therefore remains
debateable as to whether prions had been generated in
these transgenic mice or this simply represents acceleration
of a spontaneous neurodegenerative disease already poised
to occur in these mice (Nazor et al., 2005). Others
generated transgenic mice expressing endogenous levels
of mouse PrP 101L by the gene knock-in approach
(Manson et al., 1999). These mice did not develop
spontaneous neurodegeneration but were reported to show
greater susceptibility to human P102L prions than wild-
type mice (Barron et al., 2001).
However, we consider it essential to study this and other
human pathogenic mutations in human PrP, rather than in
mouse PrP where the mutation may have different
structural consequences. With respect to such models it
is important to demonstrate that human PrP is function-
ally active and can participate in prion propagation and
pathogenesis in mouse cells. Human PrP can rescue a PrP
null phenotype in mice (Whittington et al., 1995),
confirming it is functionally active and human prions
can replicate in transgenic mice expressing only human
PrP, which develop spongiform neurodegeneration
(Collinge et al., 1995).
Importantly, there are examples of IPD where the amino
acid change thought to be pathogenic is found as a normal
variant in other mammalian species (Butefisch et al., 2000;
Lysek et al., 2004; Colucci et al., 2006). There is also direct
experimental evidence that a human PRNP mutation on a
mouse background would not necessarily have the same
structural consequences in the expressed protein. The
introduction of a tryptophan residue at amino acid
position 175 in place of the native phenylalanine has been
successfully used as an optical probe for studying the
folding dynamics of the recombinantly expressed mouse
PrP (Wildegger et al., 1999). The introduction of this probe
had no measurable effect on the stability of the protein.
However, in stark contrast, when we introduced the same
mutation into the human PRNP gene, the resultant
recombinant PrP was unable to fold into the native
conformation (T. Hart, G. J. Jackson, A. R. Clarke & J.
Collinge, unpublished data). The profoundly dissimilar
consequences of the same mutation in mouse and human
PrP questions the whole approach of modelling human
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from other species. In particular, the destabilizing effects
measured in a mouse protein cannot be assumed to be
equivalent in the human protein. The present study differs
from all previous reports because we have investigated the
biological properties of naturally occurring mutations in
human PrP itself expressed in transgenic mice.
We have now generated two transgenic mouse lines that are
both homozygous for the human PrP
102L,129M expressing
transgene on a homozygous mouse PrP gene (Prnp) null
background (HuPrP
102L,129M+/+ Prnp
o/o). Similarly, we
have generated two further transgenic lines that are both
homozygous for human PrP
200K,129M transgenes, again on a
Prnp
o/o background (HuPrP
200K,129M+/+ Prnp
o/o). Here, we
report the relative susceptibilities of these transgenic mice to
classical (sporadic and iatrogenic) CJD prions, homotypic
IPD isolates and variant (v) CJD prions.
METHODS
Transgene construction. Briefly, the 759 bp human PrP ORF was
amplified by PCR with Pfu polymerase from human genomic DNA
with appropriate mutations, using forward primer 59-
GTCGACCAGTCATTATGGCGAACCTT-39 and reverse primer 59-
CTCGAGAAGACCTTCCTCATCCCACT-39. Restriction sites SalI
and XhoI (underlined) were introduced in the forward and reverse
primers, respectively, for use in subsequent cloning steps. The blunt-
ended PCR fragments generated by Pfu polymerase were subcloned
into SmaI-digested pSP72 vector and sequenced to ensure that no
spurious alterations have been introduced by the PCR other than the
expected existing point mutations. The mutant human PrP ORFs
with the appropriate point mutation confirmed were then isolated by
using SalI and XhoI. Subsequent subcloning into the cosmid vector
SHaCosTt (Scott et al., 1989) and preparation of high quality DNA of
the insert was as described previously (Asante et al., 2002).
Microinjection. The purified PRNP transgenes for P102L and E200K
both with M at polymorphic codon 129 were microinjected (Hogan et
al., 1994) into single cell eggs of a strain of mice (FVB6SV1296C57)
in which the murine PrP gene has been ablated. This was achieved by
back-crossing ZH1 Prnp knockout line (Bueler et al., 1992) to FVB/N
for five generations, breeding out Prnp and restoring homozygosity of
the knockout allele. The injected eggs were cultured to the two-cell
stage and then surgically transferred to F1 (CBA6C57BL/6) recipient
females. Two homozygous lines were established for P102L designated
Tg27 and Tg33 with mutant transgene expression levels of three and
one and a half times, respectively, compared with pooled normal
human brain levels. Similarly, two homozygous lines were established
for E200K designated Tg23 and Tg49 with relative expression levels of
three- and twofold, respectively.
Genotyping. Tail biopsies were taken from putative transgenics and
screened by PCR using human PrP-specific primers (59-GTGGCCA-
GATGGAGTGACCTGGGCCTC-39 and 59-GGCACTTCCCAGCAT-
GTAGCCG-39). Founders were confirmed by Southern blotting using
a 900 bp 39 UTR fragment as a radiolabelled probe. Lines were bred to
homozygosity and 20 mice were set aside for long-term neurological
observation.
Transmission studies. All procedures were carried out in a
microbiological containment level III facility with strict adherence
to safety protocols. A panel of inocula comprising four inherited
P102L, three sporadic and three iatrogenic CJD cases were used for
the 102L transgenic mice. For the 200K transgenic mice, two inherited
E200K and one iatrogenic CJD inocula were used. Inocula were
prepared from the brain of neuropathologically confirmed cases of
sporadic and inherited CJD with consent from relatives and with the
approval from the Institute of Neurology/National Hospital for
Neurology and Neurosurgery Local Research Ethics Committee. Mice
were anaesthetized with a mixture of halothane and O2, and
intracerebrally inoculated into the right parietal lobe with 30 mlo fa
1% (w/v) brain homogenate prepared in PBS. All mice were
thereafter examined daily for clinical signs of prion disease. Mice
were killed if exhibiting any signs of distress or once a diagnosis of
prion disease was established.
Neuropathology and immunohistochemistry. Neuropathology
and immunohistochemical analyses were done as described previously
(Asante et al., 2002, 2006) with the exception that abnormal PrP
accumulation was examined using anti-PrP monoclonal antibody
ICSM 18 (D-Gen Ltd) for P102L detection, and ICSM 35 (D-Gen
Ltd) was used for E200K detection because the latter antibody does
not recognize human PrP 102L (Wadsworth et al., 2006). Appropriate
controls were used throughout.
Immunoblotting. Brain homogenates (10%, w/v) were prepared in
Dulbecco’s PBS lacking Ca
2+ or Mg
2+ ions (D-PBS) by serial passage
through needles of decreasing diameter. Aliquots were analysed with
or without proteinase K digestion (50 or 100 mgm l
21 final protease
concentration, 1 h, 37 uC) by electrophoresis and immunoblotting as
described previously (Wadsworth et al., 2001, 2008; Hill et al., 2003,
2006). Blots were probed with anti-PrP monoclonal antibody 3F4
(Kascsak et al., 1987). For quantification and analysis of PrP
glycoforms, blots were developed in chemifluorescent substrate
(AttoPhos; Promega) and visualized on a Storm 840 phosphoimager
(Molecular Dynamics) (Wadsworth et al., 2001; Hill et al., 2003,
2006). Quantification of PrP
Sc glycoforms was performed using
ImageQuant software (Molecular Dynamics).
RESULTS
Transgenic mice expressing HuPrP 102L or 200K
do not develop spontaneous disease
We generated two homozygous transgenic mouse lines
designated Tg(HuPrP
102L,129M+/+ Prnp
o/o)-27 and
Tg(HuPrP
102L,129M+/+ Prnp
o/o)-33 that expressed human
PrP 102L,129M at three and one and a half times the
human endogenous PrP
C levels, respectively (Table 1), but
not mouse PrP.
In order to assess the possibility of spontaneous neurode-
generation, we monitored an ageing cohort of 20 unin-
oculated mice from each 102LL (homozygous for proline
to leucine 102 mutation) transgenic line. Mice that died
earlier than 400 days from intercurrent illnesses showed no
evidence of prion-related neuropathology. Importantly,
mice in the cohort survived to advanced age without
clinical or neuropathological signs of prion disease or
detectable PrP
Sc, with the oldest mouse living to more than
865 days (mean survival shown in Table 1).
We also established two homozygous transgenic lines
designated Tg(HuPrP
200K,129M+/+ Prnp
o/o)-23 and
Tg(HuPrP
200K,129M+/+ Prnp
o/o)-49 that expressed human
E. A. Asante and others
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(Table 1), compared with endogenous PrP
C levels in a
pooled normal human brain homogenate. We again set
aside 20 mutant mice from both 200KK (homozygous for
glutamic acid to lysine 200 mutation) lines and observed
them long-term. Mice that died earlier than 400 days from
intercurrent illnesses showed no evidence of prion-related
neuropathology. Again, mice in the cohort survived to an
advanced age without clinical or neuropathological signs of
prion disease or detectable PrP
Sc, with the oldest mouse
living to more than 955 days (mean survival shown in
Table 1). For both 102LL and 200KK mutant PRNP
transgenic lines, Western blot analysis (data not shown) of
samples from the brain of uninoculated mice showed
equivalent proportions of di-, mono- and non-glycosylated
PrP to that seen in Tg35 and Tg45 transgenic mice
expressing wild-type human PrP 129M (Asante et al.,
2002). These data establish that the PRNP point mutations
do not selectively destabilize a particular PrP glycoform. It
is worth noting that Tg45 mice expressing human PrP
129M at four times wild-type levels do not develop
spontaneous disease at a similar age (Asante et al., 2002).
Transgenic mice expressing HuPrP 102L are more
susceptible to prions from patients with IPD
(P102L) than to classical CJD prions
To assess the susceptibility of human PrP 102L-expressing
transgenic mice to human prions, we inoculated groups of
Tg27 and Tg33 mice intracerebrally with isolates from
patients with classical CJD and IPD (P102L). Clinical
disease with high attack rates and short incubation periods
ranging from 185 to 191 days accompanied the transmis-
sion of four different IPD P102L cases to Tg27 transgenic
mice (Table 2). In sharp contrast, challenge of Tg27 mice
with four classical CJD isolates, all resulted in incomplete
clinical attack rates and prolonged and highly variable
incubation periods ranging from 342 to 717 days.
However, with the exception of one inoculum, I026, where
two mice were not affected, all sporadic and iatrogenic
CJD-inoculated mice were scored as positive for prion
infection by one or more of the following criteria: typical
clinical signs, presence of PrP
Sc on Western blot analysis or
abnormal PrP immunohistochemistry (Table 2).
A similar pattern of differential susceptibility to prions
from patients with IPD P102L and classical CJD was also
observed in Tg33 mice, which have lower expression of
human PrP 102L (Table 3). However, compared with Tg27,
the incubation periods for prions from patients with IPD
P102L in Tg33 mice were longer by about 160 days and
clinical attack rates were lower, but this difference is
consistent with the lower transgene expression levels in this
line of transgenic mice. Importantly, the apparent trans-
mission barrier to classical CJD relative to IPD P102L
prions was again clearly observed, with mean incubation
periods for sporadic and iatrogenic CJD prions being about
200 days longer than for IPD P102L cases (Table 3).
Neuropathological examination was performed to invest-
igate whether the differential susceptibility to prions from
classical CJD and IPD P102L cases would be associated
with the development of distinct patterns of neuropatho-
logy. However, there was no discernible neuropathological
difference between Tg27 and Tg33 mice challenged with
either classical CJD or inherited P102L prions (data not
shown). Using Tg27 as a representative line, transmissions
of both classical and IPD P102L prions were characterized
by generalized synaptic PrP deposits in the cerebral cortex,
basal ganglia, hippocampus, thalamus (Fig. 2d) and to a
lesser extent, in the brain stem and cerebellum (Fig. 2a, b).
The main difference between classical CJD- and IPD
P102L-prion-inoculated transgenic mice was quantitative,
in that mice inoculated with classical CJD prions had more
intense staining than recipients of IPD P102L prions (Fig.
2a, b). In mice with high levels of PrP deposition, PrP
deposits were evident in the white matter. There was
widespread spongiosis in almost all grey matter areas, with
only the frontal lobes being spared. Multicentric plaques, a
characteristic feature of GSS and associated with IPD
P102L neuropathology was not seen in our models, with
Table 1. Characterization of mutant human PrP transgenic lines
For each line, a cohort of mice was set aside for long-term observation. 102LL homozygous for proline to leucine 102 mutation; 200KK
homozygous for glutamic acid to lysine 200 mutation; ND, not determined.
PrP sequence Tg-line Transgene copy
number*
Expression levelD Age of oldest
mouse (days)
Mean survival
(days±SEM)
Development of
spontaneous
neuropathologyd
102LL, 129MM Tg27 11 3 870 736±36 (n59) No
Tg33 5 1.5 870 679±43 (n513) No
200KK, 129MM Tg23 5 3 960 832±34 (n514) No
Tg49 ND 2 862 753±60 (n55) No
*Transgene copy number was determined in hemizygous mice.
DExpression levels presented here are homozygous levels and are relative to pooled normal human brain homogenate levels.
dEach brain was scored negative for disease-related PrP by immunohistochemistry and immunoblotting.
Prion transmissions in transgenic mice
http://vir.sgmjournals.org 549Table 2. Classical CJD and IPD P102L prion transmissions to human PrP 102LL 129M Tg27 transgenic mice
IHC, Immunohistochemistry; IB, immunoblotting; DM, dura mater; GH, growth hormone; ND, not determined.
Aetiology Inoculum Tg(HuPrP
102L,129M+/+ Prnp
o/o)-27
Code PRNP 129
genotype
Human PrP
Sc
type*
Clinical signs Incubation
period
(days±SEM)
Positive by
IHCD
Positive
by IBD
Total
affectedd
IPD P102L I1087 MV§ T1 8/8 191±0.4 ND 8/8|| 8/8
I1479 MM T1 9/9 182±3 2/2 8/8|| 8/8
I1480 MM T1 7/9 181±3 ND 9/9|| 9/9
I1476 MV§ T1 11/12 187±7 ND 12/12|| 12/12
Sporadic CJD I1200 MM T1 5/10 717±22 7/7 9/9|| 10/10
Iatrogenic
CJD
I026 (DM) MM T2 3/8 653±83 5/6 5/6|| 6/8
I020 (GH) MV T3 6/7 411±7 2/2 6/6 7/7
I021 (GH) VV T3 8/10 342±20 5/5 7/7|| 10/10
vCJD I336 MM T4 2/11 483, 498 9/9 10/11 11/11
*According to the classification of Hill et al. (2003).
DPrimary antibody was monoclonal ICSM 18 because monoclonal antibody ICSM 35 does not recognize 102L PrP
Sc (Wadsworth et al., 2006).
dPositive either by clinical signs, Western blot analysis and/or immunohistochemistry.
§PRNP mutation is on the 129M allele (Hill et al., 2006).
||Glycoform profile for all samples showed a shift towards diglycosylated dominance (Hill et al., 2006).
All positive samples propagated T4 PrP
Sc (Hill et al., 2003).
Table 3. Classical CJD and IPD P102L prion transmissions to human PrP 102LL 129M Tg33 transgenic mice
IHC, Immunohistochemistry; IB, immunoblotting; DM, dura mater.
Aetiology Inoculum Tg(HuPrP
102L,129M+/+ Prnp
o/o)-33
Code PRNP 129
genotype
Human PrP
Sc
type*
Clinical signs Incubation
period
(days±SEM)
Positive by
IHCD
Positive
by IBD
Total
affectedd
IPD P102L I1087 MV§ T1 1/8 355 3/3 8/8|| 8/8
I1088 MM T2 4/8 297±4 6/6 6/6|| 8/8
I1090 MM T2 4/8 304±13 3/3 8/8 8/8
Sporadic CJD I282 MM T1 2/3 510, 515 2/3 2/3# 2/3
I284 MV T2 1/5 547 3/4 0/5** 3/5
Iatrogenic
CJD (DM)
I020 MV T3 0/3 .445 2/2 3/3DD 3/3
*According to the classification of Hill et al. (2003).
DPrimary antibody was monoclonal ICSM 18 because monoclonal antibody ICSM 35 does not recognize P102L prions (Wadsworth et al., 2006).
dPositive either by clinical signs, Western blot analysis and/or immunohistochemistry.
§PRNP mutation is on the 129M allele (Hill et al., 2006).
||Glycoform profile for all samples was the inherited PrP
Sc pattern (Hill et al., 2006).
Glycoform profile for all samples showed a shift towards diglycosylated dominance (Hill et al., 2006).
#Two samples had the inherited PrP
Sc glycotype and differed significantly from the classical CJD type (Hill et al., 2006).
**No sample was positive by IB.
DDSignal was too weak to allow assignment of glycotypes.
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hippocampus (Fig. 2e).
Transgenic mice expressing HuPrP 200K show
similar susceptibilities to IPD (E200K) and
classical CJD prions
Groups of Tg23 and Tg49 transgenic mice were challenged
with brain homogenates from two different human IPD
E200K cases, one homozygous for PRNP 129M (designated
E200K-129MM) and the other homozygous for PRNP
129V (designated E200K-129VV). In addition, we trans-
mitted one case of iatrogenic CJD to both lines in order to
investigate its interactions with human PrP 200K.
IPD E200K-129MM inoculum (I1091) transmitted clinical
disease to 8/8 of Tg23 mice, with a short mean incubation
period of 184±3 days (Table 4). In sharp contrast, the
second IPD E200K inoculum (I093) (E200K-129VV)
produced clinical disease in only 1/4 inoculated mice with
a relatively prolonged incubation period of 437 days. There
was however 100% total infection rate because the three
clinically asymptomatic mice, which died at 410, 518 and
538 days post-inoculation, had clear evidence of subclinical
prion infection as determined either by PrP immunohisto-
chemical or Western blot analysis (Table 4). The
transmission properties of classical CJD in Tg23 mice were
distinct from that observed in human PrP 102L-expressing
transgenic mice. Here, iatrogenic CJD 129MM inoculum
(I026) produced 100% clinical attack rate and with
relatively short mean incubation period of 184±7 days
that was remarkably similar to the mean incubation period
for IPD E200K-129MM inoculum I1091. These data
suggest that, providing there is homology at residue 129
between the inoculum and the host PrP, the E200K
mutation does not introduce a transmission barrier for
classical CJD prions.
The prion transmission pattern for transgenic line Tg49 that
had a lower level of expression of human PrP 200K, also
followed a similar trend, being characterized by high clinical
attack rates and almost identical incubation periods of
344 days for iatrogenic CJD inoculum I026, and 348 days for
IPD E200K-129MM inoculum I1091 (Table 5). The
transmission barrier associated with 129V was also evident
in Tg49 mice, as challenge of this line with IPD E200K-
129VV inoculum (I093) was also characterized by only 1/6
clinical attack rate and a prolonged incubation period of
552 days, about 200 days longer than that observed for
iatrogenic CJD (129MM) in the same line (Table 5). The
apparent low transmission efficiency of IPD E200K-129VV
inoculum (I093) in both Tg23 and Tg49 mice was not due to
low prion titre, because the same inoculum caused clinical
disease in 11/11 Tg152 transgenic mice expressing human PrP
129V with a short incubation period of 187±9 days(datanot
shown). PBS-inoculated transgenic mice did not develop
clinical disease, with most mice dying from intercurrent
illnesses at advanced ages with no neuropathology.
Neuropathological examination of affected brains revealed
synaptic type PrP deposits in the cortex and thalamic
nuclei of iatrogenic CJD-inoculated Tg23 and Tg49 mice
(data not shown), and this pattern of neuropathology
closely resembled that produced in both transgenic lines by
IPD E200K-129MM inoculum (I1091) (Fig. 2g, j).
Interestingly, the only discrete PrP plaques seen were
associated with IPD E200K-129VV inoculum I093 and
these were predominantly located in the cortex and corpus
callosum (Fig. 2h, k). There were comparatively more of
Table 4. Classical CJD and IPD E200K prion transmissions to human PrP 200KK 129M Tg23 transgenic mice
IHC, Immunohistochemistry; IB, immunoblotting; DM, dura mater.
Aetiology Inoculum Tg(HuPrP
200K,129M+/+ Prnp
o/o)-23
Code PRNP 129
genotype
Human PrP
Sc
type*
Clinical signs Incubation
period
(days±SEM)
Positive by
IHCD
Positive
by IBD
Total
affectedd
Iatrogenic
CJD (DM)
I026 129MM T2 8/8 184±7 2/2 5/5§ 8/8
IPD E200K I1091 129MM T1 8/8 184±3 2/2 4/4|| 8/8
IPD E200K I1093 129VV T3 1/4 437 3/3 4/4 4/4
vCJD I336 129MM T4 3/6 578 3/3 5/5# 6/6
*According to the classification of Hill et al. (2003).
DPrimary antibody was monoclonal ICSM 35.
dPositive either by clinical signs, Western blot analysis and/or immunohistochemistry, primary antibody was ICSM 35.
§Four samples propagated inherited PrP
Sc pattern (Hill et al., 2006), one sample was positive but signal was too weak to assign glycotype.
||Three samples propagated inherited PrP
Sc pattern (Hill et al., 2006), one sample was positive but signal was too weak to assign glycotype.
All positive samples propagated the inherited PrP
Sc pattern (Hill et al., 2006).
#All positive samples propagated a novel human PrP
Sc type (designated PrP
Sc type 8) with lower molecular mass fragment size than type 4 PrP
Sc
(Hill et al., 2003).
Prion transmissions in transgenic mice
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lower expression level (Fig. 2h, k) than in the higher
expressing Tg23 line (data not shown).
PrP glycoform profiles in transgenic mice
challenged with classical CJD and IPD prions
Within the framework of the protein-only hypothesis, the
different phenotypes associated with prion strains are
thought to be determined by the propagation of distinct
PrP
Sc isoforms with divergent physico-chemical properties
(Bessen & Marsh, 1994; Collinge et al., 1996b; Telling et al.,
1996b; Safar et al., 1998; Prusiner, 1998; Hill & Collinge,
2000; Collinge, 2001; Gambetti et al., 2003; Collinge &
Clarke, 2007). IPDs with P102L and E200K mutations are
associated with a unique PrP
Sc glycoform ratio that differs
significantly from those seen in classical CJD and vCJD
(Collinge et al., 1996b; Hill et al., 2003, 2006; Wadsworth et
al., 2006). We therefore analysed PrP
Sc glycoform ratios
propagated in human PrP 102L- and 200K-expressing
transgenic mice challenged with a range of human prions.
Mice inoculated with either IPD isolates or classical CJD
isolates propagated PrP
Sc with a predominance of both di-
and monoglycosylated PrP (Fig. 1). This finding is of
particular interest in recipients of classical CJD prions
where a change in PrP
Sc glycoform ratio is apparent on
transmission (see Fig. 1b lanes 3 and 6; and Table 6). While
the primary transmission data suggest that there are
statistically significant differences in the glycoform ratios
of PrP
Sc propagated in human PrP 102L- and 200K-
expressing transgenic mice inoculated with IPD isolates
(data not shown) or classical CJD prions (Table 6), further
subpassage to transgenic mice expressing either mutant or
wild-type PrP will be required to fully interpret this
observation because of the heterogeneous nature of the
primary IPD inocula from patients’ brains used in these
Table 5. Classical CJD and IPD E200K prion transmissions to human PrP 200KK 129M Tg49 transgenic mice
IHC, Immunohistochemistry; IB, immunoblotting; DM, dura mater.
Aetiology Inoculum Tg(HuPrP
200K,129M+/+ Prnp
o/o)-49
Code PRNP 129
genotype
Human PrP
Sc
type
Clinical signs Incubation
period
(days±SEM)
Positive by
IHC*
Positive
by IB*
Total
affectedD
Iatrogenic
CJD (DM)
I026 129MM T2 6/9 344±8 4/5 8/8d 9/9
IPD E200K I1091 129MM T1 5/8 348±22 5/6 8/8d 8/8
IPD E200K I1093 129VV T3 1/6 552 4/5 6/6d 6/6
vCJD I336 129MM T4 2/6 631, 681 4/4 5/5§ 6/6
*Primary antibody was monoclonal ICSM 35.
DPositive either by clinical signs, Western blot analysis and/or immunohistochemistry; primary antibody was ICSM 35.
dAll positive samples propagated the inherited PrP
Sc pattern (Hill et al., 2006).
§All positive samples propagated a novel PrP
Sc type (designated PrP
Sc type 8) with lower molecular mass fragment size than type 4 PrP
Sc (Hill et al.,
2003).
Fig. 1. Immunoblot analysis highlighting the PrP
Sc types propa-
gated in brains of transgenic mice. Mice were inoculated with
classical CJD and prions from patients with IPD P102L and
E200K. (a) Immunoblots comparing transmission of IPD P102L
prions and classical CJD to 102LL 129M Tg27 and Tg33
transgenic mice. (b) Immunoblots comparing transmission of
human isolates from E200K-129MM, E200K-129VV and classical
CJD to 200KK 129M Tg23 transgenic mice. (c) Immunoblots
comparing transmission of IPD E200K-129MM, P200K-129VV
and classical CJD prions to 200KK 129M Tg49 transgenic mice.
(d) Immunoblots comparing transmission of vCJD prions to
transgenic lines expressing human PrP. The provenance of each
brain sample is designated above each lane. Immunoblots were
analysed by enhanced chemiluminescence with anti-PrP antibody
3F4.
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2006; Wadsworth & Collinge, 2007).
PRNP point mutations in association with 129M
do not prevent propagation of the vCJD prion
strain
To date all neuropathologically confirmed vCJD cases
have been associated with 129M homozygosity (Collinge
et al., 1996a; Collinge, 2005). We and others have
reported previously that PrP 129M homozygosity is
required for the experimental recapitulation of abundant
florid plaque formation from BSE and vCJD prion
infection (Crozet et al., 2001; Asante et al., 2002;
Wadsworth et al., 2004; Bishop et al., 2006). Notably,
overexpression is not required for florid plaque formation
(Asante et al., 2006). Furthermore, 129V has a dominant-
negative effect on the formation of florid plaques in the
PRNP 129MV heterozygous genotype, leading to dissoci-
ation between the propagation of type 4 PrP
Sc and florid
plaque formation (Asante et al.,2 0 0 6 ) .T oi n v e s t i g a t ei f
PRNP point mutations would affect the propagation of
Fig. 2. Neuropathological analysis of transgenic mouse brain by PrP immunohistochemistry. Anti-PrP monoclonal antibody
ICSM 18 was used for the 102LL transgenic brains, and ICSM 35 was used for the 200KK transgenic brains because ICSM 35
does not detect mutant 102L PrP (Wadsworth et al., 2006). Upper panels (a–c and g–i) show regional distributions of PrP
plaque deposition in 102LL 129M Tg27 and 200KK 129M Tg49 transgenic mice challenged with the various human prion
inocula with the aetiologies indicated above each panel; synaptic type PrP deposits (pink), discrete PrP plaque deposits (red),
blue box in the sketch denotes the area from which the PrP stained sections are derived. Panels (d), (e) and (f) represent PrP
monoclonal antibody ICSM 18 immunohistochemical staining in 102LL 129M Tg27 transgenic mice challenged, respectively,
with sporadic CJD, P102L and vCJD prions. Panels (j), (k) and (l) represent PrP monoclonal antibody ICSM 35
immunohistochemical staining in 200KK M129 Tg49 transgenic mice challenged, respectively, with IPD E200K-129MM,
E200K-129VV and vCJD inocula. Inserts in panels (f) and (l) show examples of florid plaques associated with the
neuropathology of vCJD prion transmissions in these mutant mice. Bar, panels (d)–(f) and (j)–(l)5200 mm.
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http://vir.sgmjournals.org 553vCJD prions and expression of characteristic pathology,
we challenged Tg27, Tg23 and Tg49 transgenic mice (all
of which are homozygous for 129M) with a previously
characterized vCJD isolate designated I336 (Tables 2, 4
and 5).
Transmission of vCJD prions to Tg27 mice resulted in only
2/11 clinical attack rate with prolonged incubation periods
greater than 482 days post-inoculation (Table 2), but 11/11
total infection rate (positive either by clinical scoring,
immunoblot or immunohistochemistry), mirroring trans-
mission properties of the same vCJD inoculum in
homozygous human PrP 129MM-expressing Tg35 and
Tg45 mice (Asante et al., 2002). Similarly, transmission of
vCJD to Tg23 and Tg49 transgenic mice resulted in 3/6 and
2/6 clinical attack rates, respectively, and with prolonged
incubation periods (Tables 4 and 5), and these were again
accompanied by 100% total infection rate in both lines, as
determined either by clinical scoring, Western blot analysis
or immunohistochemistry. Affected Tg27 mice propagated
PrP
Sc that was closely similar to type 4 PrP
Sc present in the
vCJD inoculum (Fig. 1d, lanes 1 and 3) and distinct from
type 5 PrP
Sc seen in vCJD-inoculated Tg152 mice
expressing human PrP 129V (Hill et al., 1997;
Wadsworth et al., 2004) (Fig. 1d, lane 2). In keeping with
this finding, vCJD-inoculated Tg27 mice showed neuro-
pathological changes that were characteristic of the vCJD
prion strain with extensive plaque deposition many of
which were of the florid type (Fig. 2c, f).
In vCJD challenged human PrP 200K-expressing transgenic
mice Tg23 (data not shown) and Tg49 (Fig. 2i, l), abundant
florid plaques were also observed that were indistinguish-
able from the florid plaques generated in transgenic mice
expressing wild-type human PrP 129MM, Tg35 or Tg45
(Asante et al., 2002). Interestingly, the lower human PrP
200K-129M-expressing Tg49 line had a higher PrP plaque
load than Tg23 mice, suggesting that PrP plaque density
may be related to the kinetics of PrP
Sc formation. Notably,
however, both human PrP 200K-129M-expressing lines
Tg23 and Tg49 propagated PrP
Sc with a slightly lower
molecular mass fragment size than type 4 PrP
Sc seen in the
vCJD inoculum (Fig. 1d, lanes 4 and 5). We have
provisionally designated this new PrP
Sc isoform, that
generates proteinase K-resistant fragments sharing the
glycoform ratio of types 4 and 5 PrP
Sc but with a smaller
fragment size than type 4, as human PrP
Sc type 8. Serial
passage studies will be required to establish if, like type 5
PrP
Sc, this novel PrP
Sc type represents a distinct vCJD-
derived prion strain. In this regard, it will be interesting to
see whether this distinct PrP
Sc conformer, that is associated
with abundant florid plaques in human PrP 200K-
expressing transgenic mice (Fig. 2i, l), can be maintained
on subpassage in transgenic mice expressing wild-type
human PrP.
DISCUSSION
In these studies, we have used transgenic mice homozygous
for two different human PrP mutations and devoid of
murine PrP, in order to allow a comparative study of the
transmission properties of PRNP mutations in the absence
of the confounding effects of endogenous murine PrP. Our
study differs from previous reports (Hsiao et al., 1990;
Hegde et al., 1998; Chiesa et al., 1998; Manson et al., 1999),
in that we have modelled PRNP disease-associated muta-
tions on human PrP, rather than superimposing the
human mutations on rodent PrP. This is particularly
important because destabilizing effects measured in a
mouse protein cannot be assumed to be equivalent in the
human protein (Wildegger et al., 1999; T. Hart, G. J.
Jackson, A. R. Clarke & J. Collinge, unpublished data).
Our data show that while the P102L mutation is permissive
to homotypic IPD P102L prions, there appears to be a
barrier limiting the transmission of classical CJD prions. In
contrast, the E200K mutation is equally permissive to
homotypic IPD E200K and classical CJD prions, providing
there is no mismatch at PRNP codon 129. Neither
mutation appears to influence the propagation of the
vCJD prion strain.
Previously we have shown that cases of IPD caused by the
PRNP point mutations P102L, D178N and E200K have a
unique PrP
Sc glycoform ratio following proteinase K
digestion, which differs significantly from PrP
Sc glycoform
ratios observed in sporadic, iatrogenic and vCJD or IPD
caused by octapeptide repeat insertional mutations (Hill
Table 6. Transmission of classical CJD leads to a significant alteration in PrP
Sc glycoform ratios in 200KK and 102LL transgenic
mice
PRNP mutation Classical CJD T2 MM 200KK 129M Tg23 200KK 129M Tg49 102LL 129M Tg27
None E200K E200K P102L
Diglycosylated PrP
Sc 19.6±1.0* 32.6±2.0 P,0.0001 40.9±4.0 P,0.0001 50.8±5.0 P,0.0001
Monoglycosylated PrP
Sc 47.9±1.0 48.3±2.0 P50.8 37.0±2.0 P,0.0001 36.5±2.0 P,0.0001
Unglycosylated PrP
Sc 32.6±1.0 19.1±1.0 P,0.0001 21.8±2.0 P,0.0004 12.6±3.0 P,0.0001
*Glycoform ratios of PrP
Sc propagated in transgenic mice (n53 per line) inoculated with classical CJD isolate I026 [type 2 PrP
Sc 129MM (T2 MM)]
are compared with the human T2 MM glycoform ratio (n511) (Hill et al., 2006) Data show mean±SEM. P values relate to comparison with
classical CJD T2 MM (unpaired two-tailed t-test).
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that point mutations in PRNP either destabilize non-
glycosylated PrP, in turn reducing its relative abundance
(Petersen et al., 1996), or directly dictate the stoichiometry
and packing order of the three PrP glycoforms into disease-
related fibrils or other aggregates. The latter explanation is
consistent with a conformational selection model of prion
transmission barriers (Collinge, 1999; Hill & Collinge,
2003; Collinge & Clarke, 2007) that predicts that coding
changes in PrP act to specify structural preferences for
disease-related PrP isoforms. The full spectrum of effects
that different pathogenic PRNP mutations may have still
remains unclear (Hill et al., 2006).
Importantly, our data now show that the PrP
Sc glycoform
ratio of classical CJD prions is not maintained on passage
in transgenic mice expressing PRNP 102L or 200K point
mutations. Instead PrP
Sc propagates with a glycoform ratio
closely similar to those seen in patients with P102L and
E200K IPD that is significantly different from the PrP
Sc
types present in the classical CJD inoculum. These data
support the hypothesis that prion strains propagated in
IPDs are distinct from those propagated in classical
(sporadic and iatrogenic) CJD (Hill et al., 2006). As
equivalent proportions of the PrP glycoforms are seen in
PrP
C expressed in uninoculated wild-type or mutant PRNP
transgenic mice, this change in PrP
Sc glycoform ratio is
consistent with the PRNP point mutations acting to
directly dictate the stoichiometry and packing order of
the three PrP glycoforms into disease-related fibrils or
other aggregates (Hill et al., 2006). Furthermore, previous
immunoprecipitation studies using a panel of monoclonal
antibodies suggested that the proportion of each glycoform
incorporated into PrP
Sc is probably controlled in a strain-
specific manner (Khalili-Shirazi et al., 2005).
The interpretation of primary transmission data for IPD
isolates is complicated by the heterogeneous composition
of disease-related PrP isoforms that may be present in the
primary inoculum (Hill et al., 2006; Wadsworth et al.,
2006; Wadsworth & Collinge, 2007). For example in P102L
IPD, it is now apparent that three isoforms of protease-
resistant PrP with divergent physico-chemical properties
can be propagated. Two distinct abnormal conformers
derived from PrP P102L generate protease-resistant frag-
ments of either approximately 21–30 or 8 kDa (Parchi
et al., 1998; Piccardo et al., 1998, 2007; Muramoto et al.,
2000; Hill et al., 2006; Wadsworth et al., 2006), while
abnormal conformers of wild-type PrP appear to generate
proteolytic fragments of only approximately 21–30 kDa
(Wadsworth et al., 2006). Glycoform ratios of approxi-
mately 21–30 kDa proteolytic fragments generated from
PrP P102L and wild-type PrP are not only distinct from
each other, but are also distinct from those generated from
wild-type PrP in sporadic or acquired CJD (Wadsworth
et al., 2006). Differences in neuropathological targeting of
these distinct disease-related PrP species, together with
differences in their abundance and potential neurotoxicity,
provide a molecular mechanism for generation of multiple
phenotypes in P102L IPD (Wadsworth et al., 2006;
Piccardo et al., 2007). Propagation of particular PrP
Sc
isoforms in a new host will also be determined by host
genetic background, PRNP sequence and prion strain type
(Collinge & Clarke, 2007). These data have significant
implications for interpreting the transmission properties of
IPD isolates in both conventional and transgenic mice and
may in part explain the historical differences seen in
previous transmissions of IPD isolates (Brown et al., 1994;
Tateishi et al., 1996). Serial passage studies of the prion
isolates generated here should help to clarify the major
influencing factors limiting the transmission of IPD, and
how many strains may be associated with IPDs.
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